The global market for transdermal drug delivery systems expected to attain $10.2 billion by 2029, growing at a CAGR of 3.4% over the forecast period, driven by unmet medical needs, and introduction and uptake of advanced drug delivery technologies.
- Other factors driving market growth include various advantages, such as prolonged therapeutic effect, reduced side-effects, improved bioavailability, better patient compliance and easy termination of drug therapy.
- In addition, increasing prevalence of cardiovascular diseases (CVDs), neurological disorders, osteoporosis, menopause, chronic pain, and genitourinary disorders as the population ages anticipated to propel the overall market growth during the forecast period.
Transdermal drug delivery system (TDDS) can provide controlled delivery of drugs through the skin portal to systemic circulation at a predetermined rate and maintain clinically the effective concentrations over a prolonged period of time.
- TDDS technology aimed at developing safe and efficacious means of delivering medications continues to garner investment with the continuous advancement of new and innovative approaches.
- Transdermal drug delivery (TDD) has recently emerged as an effective alternative to oral and injection administration because of its less invasiveness, low rejection rate, and excellent ease of administration. TDD has also made an important contribution to medical practice such as diabetes, hemorrhoids, arthritis, migraine, and schizophrenia treatment.
Transdermal delivery provides a leading edge over injectable and oral routes by increasing patient compliance and avoiding first-pass metabolism.
- Transdermal delivery is currently restricted to ~20 drug molecules that are approved by the US-FDA, due to challenges associated with potent pharmacological activity and correct physicochemical properties to enable skin penetration.
- The transdermal sector of the pharmaceutical drug delivery market is very small in terms of both the number of drugs delivered and revenue compared to oral, inhalation, injectable and infusion routes of drug delivery.
- Transdermal administration has the advantage of no pain, no blood, easy self-administration, low drug dosage, and high drug integrity, which greatly reduces the adverse reactions caused by oral or injection drugs.
- TDDS are being developed and studied in the treatment of obesity, Parkinsonism, diabetes, smoking cessation, analgesia, Alzheimer’s disease, hypertension, arthritis, osteoporosis, migraine, schizophrenia, and so on.
- Transdermal administration can deliver most peptides or protein drugs that cannot be taken orally.
- TDDS are being developed and studied in the treatment of obesity, Parkinsonism, diabetes, smoking cessation, analgesia, Alzheimer’s disease, hypertension, arthritis, osteoporosis, migraine, schizophrenia, and so on.
The global market for transdermal drug delivery systems report provides market size ($million 2019 to 2029), market share, trends and forecasts growth trends (CAGR%, 2023 to 2029).
The global transdermal drug delivery systems market segmented by technology (passive transdermal transport systems, active transdermal transport systems); clinical application [cardiovascular disease management, neurological disorder management, hormone replacement therapy, pain management, genitourinary disorder management]; patch-based pharmaceutical products (clonidine and nitroglycerin products, neurological disorder treatment products, estrogen replacement products, pain management products, urologic treatment products), and geography.
- The majority of TDDS on the market are based on passive diffusion technology, whereas the most active technologies are in clinical development and subsequent regulatory processes.
- There are many well documented benefits of this delivery route however, and as a result there is great interest in increasing the number of therapeutic substances that can be delivered transdermally.
- Advances in TDDSs could provide the driving force for controlling prevalence of diseases of cardiovascular and central nervous systems, diabetes, neuromuscular diseases, genetic diseases, and infectious and localized infectious diseases, while spearheading advances in vaccination and supporting patient preference for self-administration of drugs for long-term treatment.
- TDDS has significantly influenced the delivery of various therapeutic agents, especially in pain management, hormonal therapy, and treatment of diseases of the cardiovascular and central nervous systems
- Based on the clinical applications, the pain management devices segment accounted for largest share of global sales of transdermal patches, followed by the neurological disorders management segment.
- The pain management segment characterized by greater longevity of incurable and terminal cancer patients resulting from advances in primary cancer therapy and palliative care.
- However, cardiovascular disease (CVD) management segment is expected to grow at the fastest rate during the next few years, due to increasing incidences of cardiovascular disorders.
- Transdermal drug delivery leverages the advantages of injections and tablets- painlessness, minimal invasiveness and the avoidance of pre-systemic metabolism and can potentially be applied to medications used for the prevention and/or management of coronary artery disease and stroke.
- Most commercially available transdermal patches are categorized into reservoir, matrix, single- and multi-layer drug-in-adhesive, and vapor patch and microreservoir systems.
- Overall, transdermal products are used to treat a wide variety of conditions and diseases, including moderate to severe vasomotor symptoms due to menopause, dementia of the Alzheimer’s type, attention deficit hyperactivity disorder, major depressive disorder, management of chronic pain, prevention of nausea and vomiting, prevention of angina pectoris, and several others.
- Currently approved transdermal drug delivery (TDD) products in the US and Europe include Scopolamine (travel sickness), Nitroglycerin (angina), Clonidine (hypertension), Estradiol (female hormone replacement therapy), Fentanyl (chronic pain), Testosterone (hypogonadism), Nicotine (smoking cessation), Estradiol and norethindrone acetate (female hormone replacement therapy), Ethinyl estradiol and norelgestromin (female contraception), Oxybutynin (enuresis), Methylphenidate (attention deficit hyperactivity disorder), Selegiline (depression), Rivastigmine (Alzheimer’s disease), Rotigotine (Parkinson’s disease and restless leg syndrome), Granisetron (Chemotherapy-induced emesis) and Buprenorphine (moderate to severe pain).
The global transdermal drug delivery devices market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.
- Geographically, the North America region accounted for more than 75% of total TDDS market, followed by the Europe region, attributed to technological progress for the treatment of cardiovascular disease, neurological disorders, hormone replacement therapy (HRT), pain management, and genitourinary disorder management.
- In Europe, as the incidence of obesity increases and the population ages, the prevalence of hypertension and angina pectoris are expected to increase in the near future.
- On the other hand, the Asia Pacific TDDS market expected to witness promising growth potential in the coming years, owing to increasing prevalence of angina pectoris, hypertension, Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), Parkinson’s disease, menopause, osteoporosis, cancer-related pain, post-herpetic neuralgia, overactive bladder, and hypogonadism.
The global transdermal drug delivery systems market report also provides the detailed market landscape (market drivers, restraints, and opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.
Major competitors operating in the global transdermal drug delivery systems market and profiled in this report include 3M Company, Allergan, Inc., Viatris, Inc. (Mylan Technologies, Inc./Mylan NV), Noven Therapeutics, Inc., Hisamitsu Pharmaceutical Co., Inc., Novartis AG, Johnson & Johnson, Boehringer Ingelheim GmbH, Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Acrux Limited, Echo Therapeutics, Inc., and Endo Pharmaceuticals, Inc.
- Technology
- Passive Transdermal Transport Systems
- Active Transdermal Transport Systems
- Clinical Application
- Cardiovascular Disease Management (CVD)
- Neurological Disorder Management
- Hormone Replacement Therapy (HRT)
- Pain Management
- Genitourinary Disorder Management
- Patch-Based Pharmaceutical Products
- Clonidine and Nitroglycerin Products (CVD)
- Neurological Disorder Treatment Products
- Estrogen Replacement Products (HRT)
- Pain Management Products
- Urologic Treatment Products
- Geography
- North America (U.S., Canada)
- Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
- Asia Pacific (Japan, China, India, Rest of APAC)
- Latin America (Brazil, Mexico, Rest of LA)
- Rest of the World
- Company Profiles
- 3M Company
- Acrux Limited
- Allergan, Inc.
- Bayer AG
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Echo Therapeutics, Inc.
- Endo Pharmaceuticals Inc.
- GlaxoSmithKline plc
- Hisamitsu Pharmaceutical Co., Inc.
- Johnson & Johnson
- Viatris, Inc. (Mylan Technologies, Inc./Mylan N.V.)
- Novartis AG
- Noven Therapeutics, Inc.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/transdermal-drug-delivery-devices-market/
Related publications:
